We are live on ! Find out more
SLN

Silence Therapeutics
SLN

Fund managers haven’t disclosed any holdings of SLN yet.

SLN Hedge Fund Activity: Q1 2026 in Review

56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2026, worth a combined $102M — down 3.8% from $106M a quarter earlier.

Fund positioning in SLN was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 24 added to existing stakes and 11 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $5.45M. The largest seller was Vivo Capital, exiting entirely with an estimated $6.72M sold.

  • 56 institutional investors held Silence Therapeutics (SLN) as of Q1 2026, down from 58 in Q4 2025.
  • Funds reported $102M of Silence Therapeutics stock for Q1 2026, down 3.8% quarter-over-quarter.
  • 6 funds opened new Silence Therapeutics positions in Q1 2026 and 6 closed out, a net change of 0 holders.
  • The largest Silence Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $5.45M added.
  • The largest Silence Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $6.72M sold.

Based on aggregated 13F filings for Q1 2026.